Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

Abstract: The present invention is a catalyst comprising: (i) a compound comprising at least one first metal element selected from boron, magnesium, zirconium, and hafnium, and (ii) an alkali metal element, wherein the compound and the alkali metal element are supported on a carrier having silanol groups, an average particle size of the compound of the first metal element is 0.4 nm or more and 50 nm or less, the catalyst satisfies the following formula (1): 0.90×10?21(g/number)?X/(Y×Z)<10.8×10?21(g/number)??formula (1), in which X is a molar ratio of the alkali metal element to the at least one first metal element in the catalyst, Y is a BET specific surface area of the catalyst (m2/g), and Z is a number of the silanol groups per unit area (number/nm2).

Abstract: A plasma processing apparatus of an embodiment includes a chamber, an introducing part, a substrate electrode, a high-frequency power source, a low-frequency power source, and a switching mechanism. The introducing part introduces a process gas into the chamber. The substrate electrode is disposed in the chamber, a substrate is directly or indirectly mounted on the substrate electrode, and the substrate electrode includes a first and a second electrode elements alternately arranged. The high-frequency power source outputs a high-frequency voltage of 40 MHz or more for ionizing the process gas to generate plasma. The low-frequency power source outputs a low-frequency voltage of 20 MHz or less for introducing ions from the plasma. The switching mechanism applies the low-frequency voltage alternately to the first and the second electrode elements.

Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

Abstract: A damping machining method for a long workpiece includes, when rotating the long workpiece in a state in which both end portions of the long workpiece are respectively held and cutting an outer circumferential portion of the long workpiece with a turning tool, applying a torsional load to the long workpiece.

Abstract: An object of the present invention is to provide a catalyst that enables production of an unsaturated carboxylic acid and/or unsaturated carboxylic acid ester represented by methyl methacrylate with high selectivity. The object is achieved by a catalyst including: one or more elements selected from boron, magnesium, zirconium, hafnium, and titanium; one or more elements selected from alkali metal elements; and silica; the catalyst having a peak height ratio I2/I1 of 0 to 1.2, wherein I1 represents the peak height at 417±10 cm?1, and I2 represents the peak height at 1050±10 cm?1, as obtained by Raman spectroscopy.

Abstract: An ophthalmologic apparatus includes an objective measurement optical system that is configured to objectively measure eye characteristics of a subject eye; an optotype projection system that is configured to present a fixation target to the subject eye at a predetermined presentation position and apply fog to the subject eye; and a controller that is configured to control the objective measurement optical system and optotype projection system. The controller is further configured to objectively measure the eye characteristics over time by changing a presentation position of the fixation target from the predetermined presentation position in a direction to increase an amount of fog and presenting the fixation target.

Abstract: An ophthalmologic apparatus includes a subjective measurement optical system configured to measure a subjective refractive value of a subject eye, an objective measurement optical system configured to measure objective refractive characteristics of the subject eye, and a controller configured to control the subjective measurement optical system and the objective measurement optical system. The controller is further configured to measure the objective refractive characteristics of the subject eye by the objective measurement optical system and perform objective monitoring to monitor objective measurement information obtained by the measurement of the objective refractive characteristics during an RG test for checking whether or not corrected power is overcorrected or undercorrected by the subjective measurement optical system.

Abstract: An ophthalmologic apparatus includes a subjective measurement optical system configured to measure a subjective refractive value of a subject eye; an objective measurement optical system configured to measure objective refractive characteristics of the subject eye; and a controller configured to control the subjective measurement optical system and the objective measurement optical system. The controller is further configured to perform measurement of the objective refractive characteristics of the subject eye by the objective measurement optical system and perform objective monitoring to monitor objective measurement information obtained by the measurement of the objective refractive characteristics during a weakest power test in which a weakest point is being obtained by the subjective measurement optical system, a maximum visual acuity value or a set predetermined visual acuity value being readable from the weakest point.

Abstract: To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.

Abstract: Provided is a massaging tool for pets usable for pets of various sizes and various portions of pets, and having excellent maintenance property. A massaging tool for pets, which comprises two approximately cylindrical roller bodies, and a grip body having a branched supporting part which has a first and second supporting parts in the form of right and left pair, and can vary separation distance therebetween, wherein each of the first and the second supporting part supports the roller body in the freely rotatable manner so that a rotation axis of the roller body is oriented in the direction approximately vertical to the direction of the separation distance.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: The present invention is a catalyst comprising: (i) a compound comprising at least one first metal element selected from boron, magnesium, zirconium, and hafnium, and (ii) an alkali metal element, wherein the compound and the alkali metal element are supported on a carrier having silanol groups, an average particle size of the compound of the first metal element is 0.4 nm or more and 50 nm or less, the catalyst satisfies the following formula (1): 0.90×10?21 (g/number)?X/(Y×Z)<10.8×10?21 (g/number) ??formula (1), in which X is a molar ratio of the alkali metal element to the at least one first metal element in the catalyst, Y is a BET specific surface area of the catalyst (m2/g), and Z is a number of the silanol groups per unit area (number/nm2).

Abstract: A Lin28a activator includes a polysaccharide containing one or more selected from the group consisting of ribose, xylose, and derivatives thereof as an active ingredient. A dedifferentiation inducer of a monocyte includes a macrophage colony-stimulating factor and a polysaccharide containing one or more selected from the group consisting of ribose, xylose, and derivatives thereof as active ingredients. A therapeutic agent against diseases relating to damage in cells, tissues, or organs includes a polysaccharide containing one or more selected from the group consisting of ribose, xylose, and derivatives thereof as an active ingredient. A food or beverage product for preventing or alleviating diseases relating to damage in cells, tissues, or organs includes a polysaccharide containing one or more selected from the group consisting of ribose, xylose, and derivatives thereof.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: A probe is a probe having a substantially bar-like shape and includes a distal end portion with a substantially columnar shape adapted to be in contact with an inspection point provided on a device under test, a base end portion with a substantially columnar shape on an opposite side of the distal end portion, and a main body portion formed in a flat ribbon shape and extended to connect the distal end portion to the base end portion. The distal end portion is provided with a distal end surface inclined relative to and intersecting with an axial center of the probe.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

Abstract: A probe is a probe having a substantially bar-like shape and includes a distal end portion with a substantially columnar shape adapted to be in contact with an inspection point provided on a device under test, a base end portion with a substantially columnar shape on an opposite side of the distal end portion, and a main body portion formed in a flat ribbon shape and extended to connect the distal end portion to the base end portion. The distal end portion is provided with a distal end surface inclined relative to and intersecting with an axial center of the probe.